Topical difluprednate monotherapy for uveitic macular edema

Can J Ophthalmol. 2016 Feb;51(1):47-9. doi: 10.1016/j.jcjo.2015.10.007.

Abstract

Objective: To describe the use of topical difluprednate for the treatment of uveitic macular edema.

Design: Retrospective review of 3 consecutive cases of uveitic macular edema.

Methods: Patients were treated with topical difluprednate monotherapy.

Results: All patients experienced complete resolution of uveitic macular edema within 2-4 weeks. We observed a statistically significant improvement in central subfield macular thickness (p = 0.04). There was an overall improvement in visual acuity, but this result was not statistically significant (p = 0.33).

Conclusions: Topical difluprednate can be effective for uveitic macular edema. Further investigation of this therapy in prospective randomized controlled trials is warranted.

Publication types

  • Case Reports

MeSH terms

  • Administration, Topical
  • Adult
  • Female
  • Fluprednisolone / analogs & derivatives*
  • Fluprednisolone / therapeutic use
  • Glucocorticoids / therapeutic use*
  • Humans
  • Macular Edema / diagnosis
  • Macular Edema / drug therapy*
  • Macular Edema / physiopathology
  • Male
  • Ophthalmic Solutions
  • Retrospective Studies
  • Tomography, Optical Coherence
  • Uveitis, Anterior / diagnosis
  • Uveitis, Anterior / drug therapy*
  • Uveitis, Anterior / physiopathology
  • Uveitis, Intermediate / diagnosis
  • Uveitis, Intermediate / drug therapy*
  • Uveitis, Intermediate / physiopathology
  • Visual Acuity / drug effects

Substances

  • Glucocorticoids
  • Ophthalmic Solutions
  • Fluprednisolone
  • difluprednate